Key eligibility criteria were advanced papillary or follicular thyroid cancer, failure of standard therapy, and PD-L1 expression in tumor or stroma cells (assessed by immunohistochemistry). The gene discussed is CD274; the disease is thyroid gland follicular carcinoma.